Stool DNA testing ‘can be performed safely’ regardless of anticoagulant, antiplatelet use (Healio)

A new study published in Gastro Hep Advances found that multitarget stool DNA (mt-sDNA) testing for colorectal cancer remains accurate regardless of whether patients are on anticoagulant or antiplatelet medications. Researchers at Mayo Clinic analyzed data from over 11,000 patients and determined that medication use did not significantly impact the test’s positive predictive value (PPV), which stood at 31.4% for detecting advanced adenomas. These findings suggest that patients at risk for cardiovascular events can safely continue their medications while undergoing CRC screening. The article gives insights on the reliability of mt-sDNA testing in real-world settings.